Showing 4571-4580 of 20465 results for "".
- External Validation of Deep Learning for Barrett's Dysplasiahttps://reachmd.com/news/deep-learning-barretts-dysplasia/2487516/Key Takeaways External testing assessed classification across nondysplastic Barrett's esophagus, low-grade dysplasia, and high-grade dysplasia on whole slide images from three academic centers. Specificity reached 94.8% for high-grade dysplasia, while
- One-Minute Oscillometry vs Continuous Arterial Pressure Monitoringhttps://reachmd.com/news/oscillometry-continuous-arterial-pressure-monitoring/2487514/Key Takeaways One-minute oscillometric monitoring met the prespecified noninferiority criterion for the primary induction hypotension endpoint. Vasopressors, particularly phenylephrine, were used less often in the oscillometry group than in the continu
- Talquetamab and Daratumumab in Relapsed or Refractory Myelomahttps://reachmd.com/news/talquetamab-daratumumab-relapsed-refractory-myeloma/2487509/Key Takeaways Both talquetamab-containing regimens were associated with longer progression-free survival than the daratumumab-based control at interim analysis. Overall response, complete response or better, and MRD-negative complete response were high
- FDA Approves SKINVIVE by JUVÉDERM® for Treatment of Horizontal Neck Lineshttps://reachmd.com/news/fda-approves-skinvive-by-juvederm-for-treatment-of-horizontal-neck-lines/2487508/The US Food and Drug Administration (FDA) has approved SKINVIVE by JUVÉDERM® (Allergan Aesthetics, an AbbVie company) for the reduction of neck lines and improvement of neck appearance in adults aged 21 years and older, according to an announcement from the company. With the approval, SKIN
- AI Fracture Detection on CT: Review Finds Moderate To Good Accuracyhttps://reachmd.com/news/ai-fracture-detection-on-ct-review-finds-moderate-to-good-accuracy/2487488/Key Takeaways Across unselected cohorts, stand-alone AI showed moderate sensitivity and good specificity for CT fracture detection overall. Sensitivity was higher in selected cohorts and internal datasets than in external datasets, and performance vari
- Real-World Personalized SLIT Outcomes in Telemedicine Carehttps://reachmd.com/news/real-world-personalized-slit-outcomes-in-telemedicine-care/2487489/Key Takeaways The proportion reaching a 30-point or greater symptom improvement at least once increased from 28% at 12 months to 45% at 24 months. Medication use decreased over time, and more than 80% reported quality-of-life improvement across interva
- PORTEC-4a Trial Reports Molecular Profile Guided Adjuvant Treatmenthttps://reachmd.com/news/portec-4a-trial-reports-molecular-profile-guided-adjuvant-treatment/2487493/Key Takeaways Five-year vaginal recurrence was numerically higher with the molecular-profile strategy, although the prespecified non-inferiority criterion was met. Favorable profiles were assigned observation, intermediate profiles brachytherapy, and u
- Cabozantinib Triplet in Advanced RCC: Final COSMIC 313 Resultshttps://reachmd.com/news/cabozantinib-triplet-in-advanced-rcc-final-cosmic-313-results/2487490/Key Takeaways Longer progression-free survival with cabozantinib, nivolumab, and ipilimumab persisted at final follow-up, while overall survival remained comparable between groups. Objective response was higher with the triplet, but treatment-related t
- Finerenone in Glomerular Disease-Associated CKDhttps://reachmd.com/news/finerenone-in-glomerular-disease-associated-ckd/2487494/Key Takeaways Participants with investigator-reported glomerular disease within a larger nondiabetic CKD trial received finerenone 10 mg or 20 mg once daily or matching placebo. Finerenone was associated with slower eGFR decline, 42% lower albuminuria
- Vodobatinib Fails To Slow Early Parkinson Disease In Phase 2 Trialhttps://reachmd.com/news/vodobatinib-fails-to-slow-early-parkinson-disease-in-phase-2-trial/2487491/Key Takeaways Neither vodobatinib dose showed benefit over placebo on the week-40 MDS-UPDRS Part III primary endpoint. Several secondary measures also favored placebo, including shorter time to significant worsening in the high-dose group. Dis